Physician profile
Aamir Hashmat
NPI 1710983150
$10,068.33
in general payments reported to CMS, 2019-2025
45 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,004 · 2020: $1,879 · 2021: $2,158 · 2022: $1,658 · 2023: $1,346 · 2024: $704 · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,299 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,299.41 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,272.48 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $718.20 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Abbvie INC. | $713.90 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $576.31 | 2019-2024 | Nuplazid |
| Neurocrine Biosciences, INC. | $558.75 | 2020-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $508.49 | 2020-2024 | |
| Kyowa Kirin, INC. | $420.66 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $363.78 | 2019-2025 | |
| Lundbeck LLC | $312.92 | 2021-2025 | Vyepti, Rexulti |
| Medtronic USA, INC. | $304.86 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $294.74 | 2019-2022 | |
| Pfizer INC. | $294.04 | 2023-2025 | |
| Ge Healthcare | $282.61 | 2019-2022 | |
| Emd Serono, INC. | $274.60 | 2019-2025 | Mavenclad |
| Ucb, INC. | $258.63 | 2019-2025 | Rystiggo |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamir Hashmat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.